<DOC>
	<DOCNO>NCT01978964</DOCNO>
	<brief_summary>This open label phase 1b maintenance therapy study evaluate long-term safety , immunogenicity , anti-tumor effect repeat-dose vaccination ONT-10 patient demonstrate safety clinical benefit original ONT-10-001 phase 1 study .</brief_summary>
	<brief_title>Phase 1b Maintenance Therapy Study ONT-10 Patients With Solid Tumors</brief_title>
	<detailed_description>Open label Phase 1b maintenance therapy study evaluate long-term safety , immunogenicity , anti-tumor effect repeat-dose vaccination ONT-10 patient previously treat Stage 3 4 solid tumor histology associate expression MUC1 antigen describe medical literature . Patients must previously enrol Phase 1 clinical trial ONT-10-001 , complete treatment follow-up least 12 week , experience dose limiting toxicity , experienced progression disease per immune-related Response Criteria . Patients receive maintenance ONT-10 every 6 week .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Was enrolled Phase 1 clinical trial ONT10001 : complete treatment followup least 12 week experience dose limiting toxicity ( DLT ) experience progression disease per irRC1 Patients enrol retreatment cohort may experience localized disease progression treat definitive therapy return patient state stable disease . Examples include localized disease progression treat complete surgical resection , solitary brain metastasis treat complete surgical resection curative intent stereotactic radiosurgery , solitary bone metastasis treat curativedose radiation therapy . Patients enrol retreatment cohort must locally systemically stable disease follow definite local treatment . 2 . Last received ONT10 maximum 6 month ( unless approve medical monitor ) prior receive first dose maintenance retreatment cohort therapy 3 . ECOG 0 1 4 . Adequate baseline hematological parameter define white blood cell count ( WBC ) ≥ 3.5 x 103/µL , lymphocyte count ≥ 1.0 x 103/µL , platelet count ≥ 100 x 103/µL , hemoglobin ≥ 9 g/dL 5 . Adequate hepatic parameter define total bilirubin ≤ 1.5 x upper limit normal ( ULN ) aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3 x ULN 6 . Serum creatinine ≤ 1.5 x ULN 7 . Resolution prior ONT10 related toxicity ≤ Grade 1in severity 8 . If female child bear potential , negative pregnancy test screen 9 . If fertile male female childbearing potential , agree consistently use highly effective method birth control ( include birth control pill , barrier device , intrauterine device ) time consent 3 month follow last dose study drug 10 . Be able willing sign inform consent document approve institutional review board independent ethic committee ( IRB/IEC ) 1 . Has medical , social , psychosocial factor , opinion investigator , could impact safety compliance study procedures 2 . Received treatment systemic chemotherapy , experimental agent , radiation therapy ( exception palliative localize radiation therapy ) follow completion treatment ONT10001 study 3 . Known history autoimmune disease , arteritis , vasculitis , include , limited : lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) , Grave 's disease , Hashimoto 's thyroiditis , Wegener 's granulomatosis , temporal arteritis , polyarteritis nodosa 4 . Has untreated uncontrolled central nervous system ( CNS ) metastasis , include patient require glucocorticoid therapy CNS metastases 5 . Known immunodeficiency disease , include cellular immunodeficiency , hypogammaglobulinemia , dysgammaglobulinemia ; and/or hereditary congenital immunodeficiency 6 . Chronic steroid immunosuppressive therapy ( except low dose corticosteroid chronic obstructive pulmonary disease [ COPD ] topical steroid , allow ) 7 . Known positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C 8 . Administration vaccine ≤ 4 week prior first maintenance retreatment cohort dose ONT10 exception influenza , pneumococcus , Tdap</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ONT-10</keyword>
	<keyword>MUC1</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Maintenance therapy</keyword>
</DOC>